Navigation Links
ChanTest to Highlight the World's Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Assays & Cellular Targets Conference, Booth 11
Date:9/18/2008

Company CEO is featured speaker: "Case Study - Screening Ion Channels for

Safety and Efficacy" on Friday, September 26 at 11:30

CLEVELAND, Sept. 18 /PRNewswire/ -- ChanTest will feature its expanding line of ion channel services and cell lines for drug-discovery and development applications in booth 11 at the Assays and Cellular Targets conference in San Diego, September 24-26. ChanTest designed its ion channel cell lines and services to provide drug-discovery researchers the early information they need to identify the most promising target compounds and eliminate those that could ultimately cause harmful side effects. ChanTest is also working with pharmaceutical and biotech companies to help rescue shelved pharmaceutical compounds.

Dr. Arthur (Buzz) Brown, ChanTest's founder and CEO, will present a case study to conference participants entitled, "Screening Ion Channels for Safety and Efficacy," on Friday, September 26 at 11:30, as part of the conference's Ion Channel Targets track. "We are developing a library of ion channel-expressing cell lines for screening with the full range of automated patch clamp instruments and FLIPR-Tetra(r)," said Dr. Brown. "At present, 86 'books' are available and 160 will be available by June 2009. We validate each cell line for cDNA sequence, Western blot, voltage range, gating, and pharmacology. We recognize that each research program has its own unique needs and priorities, so we've designed our services and cell lines to offer the most flexibility possible. Our validated ion channels can be mixed and matched into panels according to tissue, e.g., cardiac; therapeutic area, e.g., pain; and ion channel family, e.g., TRP channels. And we draw upon our years of ion channel experience to help customers design an appropriate testing program to meet their specific scientific and budgetary goals."

ChanTest scientists were the first to prove hERG as the target for adverse cardiac events linked to non-cardiac drugs: Seldane (terfenadine), Propulsid (cisapride), and Nizoral (ketoconazole), and ChanTest pioneered the development of functional, cell-based ion channel testing as a means to predict cardiac side effects produced by non-cardiac drugs. Such testing is now a standard component of regulatory submissions prior to the approval of drugs for use in humans. ChanTest is committed to innovation, and is leading the next major advance in ion channel research and services with a $10 million program to develop the world's most extensive library or catalog of ion channels. ChanTest's expert electrophysiologists fully validate the ion channels for interrogation with functional, pharmacological, and biochemical assays.

The A/C/T Assays and Cellular Targets conference and exhibition takes place September 24-26, 2008 at the Marriott San Diego Hotel & Marina in California.

About ChanTest

The preeminent ion channel services company, ChanTest serves its drug discovery and development customers with GLP safety and automated screening assays using its library of ion channel-expressing cell lines - the most comprehensive in the world. Since its inception in 1998, ChanTest has tested more than 18,000 compounds for more than 250 global pharmaceutical and biotech companies - helping them to achieve their drug safety and discovery goals. ChanTest works in partnership with customers to speed the drug-development process, save time and money, and ultimately -- to help make better, safer drugs. Because of ChanTest's seminal role in this field, along with the company's uncompromising commitment to quality, ChanTest was named "most trusted fee-for-service provider" for ion channel screening in the HTStec Ion Channel Trends Survey for two years in a row. ChanTest is based in Cleveland, Ohio. For more information, please visit http://www.chantest.com.


'/>"/>
SOURCE ChanTest
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Ion Channel Targets, Booth 5
2. ChanTest Launches New Business to Provide Validated Ion Channel Expressing Cell Lines to the Research Community
3. ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Drug Discovery Technology, Booth 839
4. ChanTest Launches Redesigned Web Site
5. ChanTest to Highlight Most-Comprehensive Range of Ion Channel Profiling Screens and Consultation Services at 14th Annual SBS Conference, Booth 1104
6. ChanTest to Highlight Expanded Ion Channel Testing Services for Preclinical Safety at ToxExpo, Including the Worlds Largest Catalog of Validated Ion Channels, Booth 2504
7. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
8. New Study by BioTrends Highlights Anemia Practice Patterns According to Anemia Managers in Both Dialysis Units and CKD Clinics/Offices
9. Neuralstem Reports Second Quarter Financial Results and Highlights
10. DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature
11. Informed Medical Communications Highlights Opportunity in Revised PhRMA Code
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... , May 26, 2016  Agriculture nutrients are in ... Moines, Iowa is running their nitrate removal ... Lake Erie and coastal regions nationwide are ... preventing this widespread issue. NECi Superior Enzymes, ... Upper Peninsula, developed a new, easy to use device ...
(Date:5/26/2016)... Jersey and READING, England ... Indegene ( http://www.indegene.com ), a leading global ... life science, pharmaceutical and healthcare organisations and TranScrip ... innovative scientific support throughout the product lifecycle, today ... the launch of IntraScience.      (Logo: ...
(Date:5/26/2016)... YORK , May 26, 2016 ... today that it will be a featured presenter at the ... in New York City at the ... Denis Corin , Q BioMed Inc. CEO, is scheduled to ... will cover the company,s business strategy, recent developments and outline ...
(Date:5/26/2016)... -- Despite the volatility that continues to envelop ... pre-market research on ActiveWallSt.com directs the investor community,s focus on ... RDUS ), Cerus Corp. (NASDAQ: CERS ), Arrowhead ... Therapeutics Inc. (NASDAQ: FPRX ). Register with us ... http://www.activewallst.com/ On Wednesday, shares in ...
Breaking Biology Technology:
(Date:5/24/2016)... IRVINE, Calif. , May 24, 2016 Ampronix facilitates superior patient care ... LMD3251MT  3D medical LCD display is the latest premium product recently added to ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
Breaking Biology News(10 mins):